{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:40:20Z","timestamp":1792514420574,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Molecular Oncology"],"abstract":"<jats:p>\n                    Angiogenesis is a major driver of tumor progression and a validated therapeutic target in highly vascularized cancers such as clear cell renal cell carcinoma. However, the clinical benefit of antivascular endothelial growth factor therapies is limited by the emergence of resistance. We identified a vascular endothelial growth factor A splice variant, termed Lymphatic and Vascular Resistance Factor (LVRF), which promotes both angiogenesis and lymphangiogenesis and is upregulated following anti\u2010angiogenic treatment. To therapeutically target this pathway, we generated fully human monoclonal antibodies against LVRF. Lead antibodies displayed high specificity and nanomolar affinity and effectively inhibited LVRF\u2010driven biological activities. Anti\u2010LVRF antibodies reduced renal carcinoma cell invasion, inhibited vascular and lymphatic endothelial responses, and suppressed lymphatic endothelial cell sprouting.\n                    <jats:italic>In vivo<\/jats:italic>\n                    , treatment significantly reduced the growth of bevacizumab\u2010resistant renal carcinoma xenografts, induced regression of blood and lymphatic vessels, and decreased metastatic dissemination in zebrafish models. These findings identify LVRF as a mediator of resistance to anti\u2010angiogenic therapy and support therapeutic targeting of LVRF as a novel strategy for vascularized tumors resistant to current antivascular endothelial growth factor treatments.\n                  <\/jats:p>","DOI":"10.1002\/1878-0261.70343","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:41:41Z","timestamp":1792510901000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0985-1835","authenticated-orcid":false,"given":"Marion","family":"David","sequence":"first","affiliation":[{"name":"Kekkan Biologics  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Karaulic","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6972-3788","authenticated-orcid":false,"given":"Audrey","family":"Bennetot","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Fournier","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Odet","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081, 3D\u2010Hub\u2010S platform  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Gouraud","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bourget","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081, 3D\u2010Hub\u2010S platform  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Gaggioli","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081  France"},{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081, 3D\u2010Hub\u2010S platform  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Giuliano","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Luciano","sequence":"additional","affiliation":[{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"L\u00e9ger","sequence":"additional","affiliation":[{"name":"Kekkan Biologics  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaki","family":"Sellam","sequence":"additional","affiliation":[{"name":"Kekkan Biologics  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Pag\u00e8s","sequence":"additional","affiliation":[{"name":"Kekkan Biologics  Strasbourg France"},{"name":"University C\u00f4te d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN) UMR CNRS 7284\/U INSERM 1081  France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(02)70065-1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2917-7_1"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.11.012"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60229-4"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0211-5"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.5511"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7849"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.01.021"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2505"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.054"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.04.033"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2223"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.01.014"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2015.1085742"},{"issue":"13","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/onc.2011.360","article-title":"Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab\/Avastin treatment: the role of CXCL cytokines","volume":"31","author":"Grepin R","year":"2012","journal-title":"Oncogene"},{"issue":"3","key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.7150\/thno.38346","article-title":"The combination of bevacizumab\/Avastin and erlotinib\/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor","volume":"10","author":"Grepin R","year":"2020","journal-title":"Theranostics"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3088"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13401"},{"issue":"9","key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.7150\/thno.125269","article-title":"Connective tissue growth factor contributes to resistance to anti\u2010angiogenic therapies in renal cancer","volume":"16","author":"Teisseire M","year":"2026","journal-title":"Theranostics"},{"issue":"4","key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.7150\/thno.29093","article-title":"Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5","volume":"9","author":"Giuliano S","year":"2019","journal-title":"Theranostics"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2026.102834"},{"issue":"6","key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"9174","DOI":"10.18632\/oncotarget.13942","article-title":"Targeting the pro\u2010angiogenic forms of VEGF or inhibiting their expression as anti\u2010cancer strategies","volume":"8","author":"Guyot M","year":"2017","journal-title":"Oncotarget"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00290-9"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00241-2"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313906"},{"issue":"1","key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2518245","article-title":"Adjuvant Pembrolizumab plus Belzutifan for Renal\u2010Cell Carcinoma","volume":"395","author":"Choueiri TK","year":"2026","journal-title":"N Engl J Med"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205128"},{"issue":"12","key":"e_1_2_11_43_1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1001\/jamaoncol.2023.4437","article-title":"Sustained survival benefit in recurrent Medulloblastoma by a metronomic antiangiogenic regimen: a nonrandomized controlled trial","volume":"9","author":"Peyrl A","year":"2023","journal-title":"JAMA Oncol"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041415"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-05004-1"}],"container-title":["Molecular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70343","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1878-0261.70343","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:41:43Z","timestamp":1792510903000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1878-0261.70343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":44,"alternative-id":["10.1002\/1878-0261.70343"],"URL":"https:\/\/doi.org\/10.1002\/1878-0261.70343","archive":["Portico"],"relation":{},"ISSN":["1574-7891","1878-0261"],"issn-type":[{"value":"1574-7891","type":"print"},{"value":"1878-0261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2026-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1878-0261.70343"}}